Online inquiry

IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11519MR)

This product GTTS-WQ11519MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets FGFR3 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000142.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2261
UniProt ID P22607
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ11519MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7810MR IVTScrip™ mRNA-Anti-env, GS-HIV(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GS-HIV
GTTS-WQ13784MR IVTScrip™ mRNA-Anti-MSTN, REGN-1033(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN-1033
GTTS-WQ5846MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CHIR-12,12
GTTS-WQ5488MR IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CDP 6038
GTTS-WQ10888MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MABp1
GTTS-WQ12067MR IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MOR-00208
GTTS-WQ10879MR IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MAb-14.18
GTTS-WQ1576MR IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ACE-083
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW